Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks and vice-versa.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• You are an outpatient diagnosed with stable schizophrenia.

• You are a male or female in the age of 18 to 65 years old.

• You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.

• You must be able to take olanzapine orodispersible in a single daily dose.

• You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.

Exclusion Criteria:

• You have used olanzapine in the past and are no longer using it because of a bad reaction.

• You have known Human immunodeficiency virus positive (HIV+) status.

• You have known uncorrected, narrow angle glaucoma.

• You have known Leukopenia, (abnormally low white blood cell count).

• You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)

• You have Parkinson's disease.

• You are a female patient who is either pregnant or nursing

• You are taking medications that are not allowed in the study.